Saniona AB - Asset Resilience Ratio

Latest as of December 2025: 85.45%

Saniona AB (SANION) has an Asset Resilience Ratio of 85.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SANION working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr580.82 Million
≈ $62.51 Million USD Cash + Short-term Investments

Total Assets

Skr679.74 Million
≈ $73.15 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Saniona AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see SANION total asset value.

Liquid Assets Composition Over Time

This chart breaks down Saniona AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore SANION strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr580.82 Million 85.45%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr580.82 Million 85.45%

Asset Resilience Insights

  • Very High Liquidity: Saniona AB maintains exceptional liquid asset reserves at 85.45% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Saniona AB Industry Peers by Asset Resilience Ratio

Compare Saniona AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Dianthus Therapeutics Inc.
NASDAQ:DNTH
Biotechnology 63.98%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 62.24%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%
Wecome Pharmaceutical Co Ltd
SHE:300878
Biotechnology 0.67%
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Biotechnology 86.66%
Relmada Therapeutics Inc
NASDAQ:RLMD
Biotechnology 95.25%
MediWound Ltd
F:M8W
Biotechnology 56.04%

Annual Asset Resilience Ratio for Saniona AB (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Saniona AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 85.45% Skr580.82 Million
≈ $62.51 Million
Skr679.74 Million
≈ $73.15 Million
-3.82pp
2024-12-31 89.26% Skr303.26 Million
≈ $32.64 Million
Skr339.73 Million
≈ $36.56 Million
+40.99pp
2023-12-31 48.27% Skr30.96 Million
≈ $3.33 Million
Skr64.14 Million
≈ $6.90 Million
-22.38pp
2022-12-31 70.65% Skr108.59 Million
≈ $11.69 Million
Skr153.70 Million
≈ $16.54 Million
-10.50pp
2021-12-31 81.15% Skr357.27 Million
≈ $38.45 Million
Skr440.25 Million
≈ $47.38 Million
-1.45pp
2020-12-31 82.60% Skr571.77 Million
≈ $61.53 Million
Skr692.18 Million
≈ $74.49 Million
+33.47pp
2019-12-31 49.13% Skr47.17 Million
≈ $5.08 Million
Skr96.00 Million
≈ $10.33 Million
-11.87pp
2018-12-31 61.00% Skr50.68 Million
≈ $5.45 Million
Skr83.08 Million
≈ $8.94 Million
+27.32pp
2017-12-31 33.68% Skr16.29 Million
≈ $1.75 Million
Skr48.38 Million
≈ $5.21 Million
-41.58pp
2016-12-31 75.26% Skr53.26 Million
≈ $5.73 Million
Skr70.77 Million
≈ $7.62 Million
--
pp = percentage points

About Saniona AB

ST:SANION Sweden Biotechnology
Market Cap
$148.54 Million
Skr1.38 Billion SEK
Market Cap Rank
#17784 Global
#303 in Sweden
Share Price
Skr10.00
Change (1 day)
-0.10%
52-Week Range
Skr10.00 - Skr27.50
All Time High
Skr52.03
About

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more